Study for CLDN18.2-positive advanced gut cancers after first treatment
Treatments studied
Part of Cancer, Digestive system clinical trials.
This Phase 2 trial tests a combination anti-cancer medicine (LM-302) plus other anti-tumor treatments for advanced gastrointestinal cancers. It’s designed for people whose tumors test positive for CLDN18.2 and who have already tried standard first-line treatment but didn’t respond or couldn’t tolerate it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 to 80 and willing to sign informed consent before any study tests.
- Advanced gastrointestinal cancer confirmed by pathology (biopsy), and you’ve had first-line standard treatment that failed or you couldn’t tolerate it.
- Your tumor must test positive for CLDN18.2.
- You can do daily activities fairly normally (ECOG performance status 0–1) and have at least 3 months expected survival.
- You must have at least one measurable tumor spot on scans, and your blood/organ function must be within required ranges on labs taken within 7 days before the first dose.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of three drugs (LM-302, Candonilimab, and Capecitabine) as the first treatment for advanced stomach cancer that has a specific protein (Claudin 18.2). It aims to see if the combination shrinks tumors and is safe.
This trial tests a new drug called IBI343 combined with other treatments for people with advanced solid tumors that are CLDN18.2-positive. It aims to see if the combination can help shrink or control the cancer.
This Phase 1 study tests SKB315 to treat advanced solid tumors, with special focus on stomach/gastroesophageal junction cancer that has high CLDN18.2 in tumor tissue. It may help you if standard treatments have not worked or are not available, though early-phase studies mainly look at safety and the best way to dose.
This trial tests a new approach for stomach cancer that hasn't spread. You'd get a combination of an investigational drug targeting a specific protein on cancer cells, an immunotherapy that helps your immune system fight cancer, and standard chemotherapy before surgery. The goal is to see if this makes the tumor shrink more and improves outcomes.
This trial tests a new drug combination for stomach or gastroesophageal junction cancer that has spread or cannot be removed by surgery. It aims to see if adding LM-302 to standard treatments helps people whose tumors have a specific protein called CLDN18.2.
This trial tests a combination of experimental drugs (IBI343, Sintilimab, and chemotherapy) before and after surgery for a specific type of stomach cancer that is CLDN18.2 positive. The goal is to see if this treatment shrinks the tumor and helps prevent the cancer from coming back.
Hear when a new Malignant Neoplasms of Digestive Organs trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.